Tharimmune (NASDAQ:THAR) Announces Quarterly Earnings Results

Tharimmune (NASDAQ:THAR) posted its earnings results on Tuesday. The company reported ($2.02) earnings per share for the quarter, Zacks reports.

Tharimmune Stock Down 1.0 %

THAR traded down $0.02 during trading on Thursday, hitting $1.43. The company’s stock had a trading volume of 3,145 shares, compared to its average volume of 353,463. Tharimmune has a twelve month low of $1.28 and a twelve month high of $7.46. The business’s fifty day simple moving average is $1.75 and its 200 day simple moving average is $2.12.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on THAR shares. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th. Rodman & Renshaw assumed coverage on shares of Tharimmune in a research note on Friday, December 6th. They issued a “buy” rating and a $17.00 target price for the company.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).